New Delhi: Through a recent notification, the apex drug price regulatory agency, the National Pharmaceutical Pricing Authority (NPPA) has fixed the retail price of 59 drug formulations in combination with Paracetamol, Metformine, Atorvastatin, Rosuvastatin and others under the Drugs Prices Control Order (DPCO), 2013, exclusive of goods and services tax (GST).
The formulations whose prices have been fixed by NPPA are combination drugs. The list mentions a combination of Acetaminophen (Paracetamol) and Tramadol Hydrochloride Tablets, Glimepiride and Metformine Tablet (Gluformin G 0.5), Telmisartan and Metoprolol Tablet, Metformin Hydrochloride, Gliclazide and Pioglitazone Tablet (Reclimet PG-60 ), Atorvastatin Calcium and Clopidogrel Capsule (MACTOR CV 10), Vildagliptin and Metformin Tablet (GLUVILDA M 500 / VIGLUCOZ M 500), Rosuvastatin and Clopidogrel Capsule, Paracetamol and Phenylephrine Sachet and so on.
Various drugmakers including Dr Reddy's Laboratories (Dr Reddys Labs), Cipla, Torrent Pharma, Emcure, Abbott, Intas Pharma, Eris Lifesciences, Sun Pharma, Macleods Pharma, Hetero Labs, Wockhardt, Panacea Biotech are involved in manufacturing the said formulations under different brand names.
For instance, formulations mentioned in the list is indicated for the treatment of Type 2 Diabetes, to reduce the level of bad cholesterol, treat low blood calcium levels, upset stomach, pain management drug, decrease the amount of HIV in body and so on.
(a) The manufacturer of above-mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above-said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
• Email: info@medicaldialogues.in • Phone: 011 - 4372 0751
This site complies with the HONcode standard for trustworthy health information: verify here.
Search only trustworthy HONcode health websites: